miRNAs in secondary hyperparathyroidism: literature review
- PMID: 40394480
- PMCID: PMC12093776
- DOI: 10.1186/s12882-025-04177-1
miRNAs in secondary hyperparathyroidism: literature review
Abstract
Secondary hyperparathyroidism (SHPT) is a common complication of Chronic kidney disease (CKD), which is mainly manifested by the overproduction of Parathyroid hormone (PTH), leading to multi-system pathologies such as calcium and phosphorus metabolism disorders, skeletal lesions, and cardiovascular diseases, which seriously affects the quality of life of patients. In recent years, the role of microRNAs (miRNAs) in the pathogenesis of SHPT has been gradually revealed, providing new research directions for diagnosing and treating the disease. miRNAs play an important role in the development of SHPT by regulating genes related to calcium-phosphorus metabolism, influencing the stability and translational efficiency of PTH mRNAs, and regulating the proliferation and apoptosis of parathyroid cells. miRNA-based gene therapy strategies (e.g., miRNA antagonists or mimics) have shown promising therapeutic effects in animal models, but their clinical translation still faces challenges such as targeted delivery and safety. This review aims to summarize the mechanistic roles of miRNA and the progress of research in SHPT studies to provide a theoretical basis for diagnosing and treating SHPT.
Keywords: Gene therapy; Hyperparathyroidism; Secondary; miRNAs.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Consent to participate: Not applicable. Consent to publish: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.J Manag Care Pharm. 2007 Jun;13(5):397-411. doi: 10.18553/jmcp.2007.13.5.397. J Manag Care Pharm. 2007. PMID: 17605511 Free PMC article. Review.
-
Post-transcriptional mechanisms regulating parathyroid hormone gene expression in secondary hyperparathyroidism.FEBS J. 2020 Jul;287(14):2903-2913. doi: 10.1111/febs.15300. Epub 2020 Apr 9. FEBS J. 2020. PMID: 32191397 Review.
-
Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.Ther Apher Dial. 2019 Aug;23(4):309-318. doi: 10.1111/1744-9987.12772. Epub 2018 Dec 18. Ther Apher Dial. 2019. PMID: 30411503 Review.
-
Management of secondary hyperparathyroidism: how and why?Clin Exp Nephrol. 2017 Mar;21(Suppl 1):37-45. doi: 10.1007/s10157-016-1369-2. Epub 2017 Jan 2. Clin Exp Nephrol. 2017. PMID: 28044233 Review.
-
Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Drugs. 2016 May;76(8):841-52. doi: 10.1007/s40265-016-0575-2. Drugs. 2016. PMID: 27142279 Review.
References
-
- Corbetta S, Lania A, Filopanti M, Vicentini L, Ballaré E, Spada A. Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. J Clin Endocrinol Metab. 2002;87(5):2201–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources